AJ Vaccines lends support to Alv B for upcoming cancer vaccine trial in dogs, by supplying key component free of charge.
OSLO 07.09, 2022 – Alv B AS is preparing to enter clinical trials for its Alvacan series of autologous vaccines for the treatment of solid tumors in dogs. The vaccines are tailored to the individual patient, and are produced in part by utilizing the patient’s own cells. The indications treated in the trial are Canine Mammary Gland Carcinoma, Soft Tissue Sarcoma, other Soft tissue Sarcoma, and Histiocytic Sarcoma.
In order to enhance the potential effect of the vaccines, AJ Vaccines will supply Alv B with a potential adjuvant, free of charge for the duration of the clinical trial. In return, Alv B will use AJ Vaccine as a supplier when the product series enters its commercial phase. In addition, AJ Vaccines supports Alv B with information about methods, data, and other information that is relevant towards the use of their products.
About AJ Vaccines A/S
AJ Vaccines is a global pharmaceutical company, established in 2017 after the acquisition of Statens Serum Institut (SSI) vaccine production. Today, AJ Vaccines has state-of-the-art production with 100 years of experience in producing high quality vaccines and biologics.
AJ Vaccines is headquartered in Copenhagen, Denmark and has 600+ employees globally.
For more info: https://ajvaccines.com
About Alv B AS
Alv B is a biotech company that develops cutting-edge cancer therapeutics for companion animals. Since the company’s establishment in 2020, it has already fostered ties with some of the largest clinical practices in Europe, and has a goal of swift global expansion.
Alv B is headquartered in Oslo, Norway.
